Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1
暂无分享,去创建一个
L. Myer | S. Khoo | C. Orrell | L. Dickinson | H. Pertinez | H. Reynolds | E. Hodel | M. Lamorde | L. Else | S. Walimbwa | C. Waitt | J. Kaboggoza | A. Amara | J. Gini | J. Byamugisha | T. Malaba | Yashna Singh | K. Kintu | Mary Sihlangu | Julie-Anne Coombs | C. Heiberg | Ritah Isabella Johnson Emmanuel Nakijoba Kyohairwe Magoola Ssempija | R. Nakijoba | I. Kyohairwe | Johnson Magoola | Emmanuel Ssempija
[1] L. Myer,et al. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. , 2020, The lancet. HIV.
[2] L. Myer,et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study) , 2019, PLoS medicine.
[3] N. Qiu,et al. Characterization of the Ontogeny of Hepatic UDP‐Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes , 2019, Journal of clinical pharmacology.
[4] L. Myer,et al. Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. , 2018, Bioanalysis.
[5] S. Lockman,et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study , 2018, The Lancet. Global health.
[6] N. Parrott,et al. The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling , 2018, Clinical Pharmacokinetics.
[7] A. Hill,et al. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review , 2018, Journal of virus eradication.
[8] E. Barr,et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV , 2018, AIDS.
[9] R. Kobbe,et al. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. , 2016, AIDS.
[10] S. Khoo,et al. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[11] T. F. Rinke de Wit,et al. Prevalence and dynamics of the K65R drug resistance mutation in HIV-1-infected infants exposed to maternal therapy with lamivudine, zidovudine and either nevirapine or nelfinavir in breast milk. , 2016, The Journal of antimicrobial chemotherapy.
[12] G. Maartens,et al. Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy , 2015, Southern African journal of HIV medicine.
[13] S. Caritis,et al. Pharmacokinetics of drugs in pregnancy. , 2015, Seminars in perinatology.
[14] Qingling Chen,et al. Early Initiation of ARV During Pregnancy to Move towards Virtual Elimination of Mother-to-Child-Transmission of HIV-1 in Yunnan, China , 2015, PloS one.
[15] O. AndersonPhilip,et al. Variation of milk intake over time: clinical and pharmacokinetic implications. , 2015 .
[16] S. Piscitelli,et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients , 2015, British journal of clinical pharmacology.
[17] J. Blanco,et al. Genetic barrier to resistance for dolutegravir. , 2015, AIDS reviews.
[18] A. Kashuba,et al. Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir , 2013, Clinical Pharmacokinetics.
[19] D. Moodley,et al. Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants , 2013, The Pediatric infectious disease journal.
[20] S. Piscitelli,et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults , 2011, AIDS.
[21] A. Collier,et al. The Development of UDP-Glucuronosyltransferases 1A1 and 1A6 in the Pediatric Liver , 2011, Drug Metabolism and Disposition.
[22] M. Paech,et al. Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk , 2011, European Journal of Clinical Pharmacology.
[23] M. Fowler,et al. HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis , 2011, PLoS medicine.
[24] O. Spigset,et al. Antidepressant Use During Breastfeeding , 2011, Current women's health reviews.
[25] S. Piscitelli,et al. Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.
[26] T. Cheetham,et al. Milk Intake and Feeding Behavior in the First Week of Life and Its Relationship to Cord Blood Ghrelin, Leptin, and Insulin Concentrations , 2007, Pediatric Research.
[27] S. Duffull,et al. Prospective evaluation of a model for the prediction of milk:plasma drug concentrations from physicochemical characteristics. , 1992, British journal of clinical pharmacology.
[28] J. T. Wilson,et al. Determinants and consequences of drug excretion in breast milk. , 1983, Drug metabolism reviews.